Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …

New Approaches to Chronic Hepatitis B | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …

Background & Aims The risk of serious clinical outcomes following cessation of nucleos (t)
ide analogues (NUCs) in individuals with chronic hepatitis B remains poorly characterized …

Hepatocellular carcinoma reduced, HBsAg loss increased, and... : Hepatology Hepatocellular
carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis …

The estimated world prevalence of hepatitis B virus (HBV) infection is 316 million. HBV
infection was identified in 1963 and nowadays is a major cause of cirrhosis and …

Background Finite nucleos (t) ide analogue (NUC) therapy has been proposed as an
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …

Introduction Both entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line
therapies for chronic hepatitis B (CHB), but their comparative effectiveness with regards to …

Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …

The current treatment of chronic HBV infection, pegylated interferon-α (pegIFNα) and
nucleos (t) ide analog (NA), can suppress HBV replication, reverse liver inflammation and …